18 results about "Enteropathy" patented technology

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The present invention relates to pharmaceutical compounds of Formula (I):as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of aryl hydrocarbon receptor (AhR) and to treat conditions comprising inflammation inside the intestinal tract and certain disorders of the central nervous system affected by the gut-brain axis, including IBD, ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ischemic bowel disease as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 50-200 parts of radix salviae miltiorrhizae, 50-200 parts of caulis sargentodoxae, 50-200 parts of cortex moutan, 50-200 parts of radix paeoniae rubra and 100-250 parts of radix astragali. The traditional Chinese medicine composition disclosed by the invention has the effects of promoting blood circulation to remove blood stasis, promoting qi circulation to relieve pain, tonifying spleen and clearing damp, and can be used for clinically treating ischemic bowel disease and liver and lung injury caused by intestinal ischemia.

A method for identifying the risk of chronic enteropathy, includes receiving new patient data, receiving a machine-learning based diagnostic model and a knowledge based diagnostic model, determining whether the machine-learning based diagnostic model indicates a risk for chronic enteropathy for the new patient data, and in a case where the machine-learning based diagnostic model indicates a risk for chronic enteropathy for the new patient data, assessing the risk of chronic enteropathy using the knowledge based diagnostic model.

A method for treating and / or improving inflammatory intestinal disease includes administering a composition to a patient suffering from inflammatory intestinal disease to be capable of effectively inhibiting the patient's intestinal bleeding, intestinal inflammation, and capable of achieving efficacies of repairing intestinal cells and intestinal wall structure. The composition contains an effective amount of bromelain and / or an effective amount of Bidens pilosa extract.

The utility model belongs to the technical field of stoma drainage tubes, and particularly relates to a lavage drainage device for intestinal diseases, which comprises a communication box, a first lavage tube is fixedly mounted at the top of one side of the communication box, a drainage tube is fixedly mounted in the communication box, a second lavage tube is fixedly mounted at the bottom of the other side of the communication box, and a drainage tube is fixedly mounted in the second lavage tube. The drainage tube is sleeved with the second lavage tube, a liquid storage cavity is formed in the communicating box, a circular clamping frame is fixedly installed at the tail end of the second lavage tube, and a plurality of liquid leakage holes are formed in the bottom of the circular clamping frame. Through the structural design of the communicating box, the first lavage tube, the drainage tube, the second lavage tube, the liquid storage cavity, the circular clamping frame and the liquid leakage hole, the function of reducing discomfort of a patient is achieved, lavage and drainage can be completed at the same time through one insertion point, the puncture frequency and wounds caused by puncture are reduced, meanwhile, an open area exposed in the external environment is reduced, and the operation is convenient. Therefore, the infection risk is reduced.

The application discloses sulfhydrylated oxidized guar gum / sodium alginate microspheres and a preparation method and application thereof, and belongs to the field of biomedical materials. The sulfhydrylated oxidized guar gum and a sodium alginate base material are used to prepare and construct microspheres with pH response, colon targeting and intestinal adhesion by an emulsion gel method, the microsphere technology is used to embed probiotics, and the survival rate of the probiotics in gastric juice is improved. Through in-vitro verification, the method of embedding the microspheres successfully prevents the direct contact of the probiotics with a harsh environment, improves the ability of the probiotics to resist strong acid in the gastrointestinal tract, and enhances the adhesion and colonization effect of the probiotics in the intestinal tract. Through an animal experiment of simulating colitis, the LGG microspheres have the best treatment effect on colitis. Compared with a large number of side effects caused by antibiotic therapy, the treatment method has a certain clinical application prospect as a means with biological safety to treat inflammatory bowel disease.

The present invention relates to a compound of Formula (I), in particular, the compound of Formula (II) or an isotopic variant, a pharmaceutically acceptable salt or solvate thereof for use in a method of treatment of bile acid diarrhea (BAD) or autoimmune enteropathy (AIE) in a subject in need thereof.

The application discloses a kind of polydopamine-coated inulin-chitosan composite microspheres loaded with garlic exosomes and a preparation method and application thereof, the composite microspheres are formed by Schiff base reaction of aldehyde inactivated inulin and chitosan to form hydrogel framework, embedding garlic-derived exosome-like nanoparticles inside, and coating polydopamine layer on the surface.The application is prepared by microfluidic electrospray technology, and the obtained microspheres have uniform particle size, controllable structure and good biocompatibility.The composite microspheres are stable in gastric juice, degrade responsively in colon environment and release exosomes, and the polydopamine layer enhances intestinal mucosa adhesion and retention.The microspheres have anti-inflammatory, antioxidant, macrophage polarization regulation, intestinal barrier repair and intestinal flora regulation functions, and can be used for preparing drugs or oral preparations for preventing or treating inflammatory bowel disease (especially colitis).

The present invention relates to a feed composition for preventing or improving chronic enteropathy and adverse dietary reactions, wherein, according to one aspect, the feed composition for preventing or improving chronic enteropathy and adverse dietary reactions may include omega-3 fatty acids and butyric acid.

The disclosure provides methods and materials for detecting endogenous IgA antibodies to one or more, or all, of OmpC (ACA), Ki67 (AKiA), TK1, integrin (AINTA) and keratin (AKERA), which are useful to

To provide pharmaceutical formulations for treating or preventing C5-related diseases. [Solution] A pharmaceutical formulation for use in a method of treating CD55 deficiency accompanied by complement hyperactivation, vascular thrombosis, and protein-losing enteropathy (CHAPLE disease) in a subject, wherein the pharmaceutical formulation comprises an antibody or antigen-binding fragment thereof that specifically binds to C5 and includes three heavy chain complementarity-determining regions of a heavy chain variable region (HCVR) containing a specific amino acid sequence, and three light chain complementarity-determining regions of a light chain variable region (LCVR) containing a specific amino acid sequence, wherein the subject has hypoalbuminemia and is determined to have a CD55 loss-of-function mutation by genetic analysis.

The application relates to the field of intelligent medical treatment, in particular to a method, equipment and program product for identifying rare intestinal diseases. The method comprises the following steps: acquiring pathological data of a to-be-detected person; the pathological data comprises goblet cells, Paneth cells, neutrophilic granulocytes and plasma cells; the type of the rare intestinal disease of the to-be-detected person is determined based on the pathological data, the type of the rare intestinal disease comprises autoimmune enteropathy and common variant immunodeficiency; when any two or more of the following conditions are met, namely, the number of goblet cells is less than a preset threshold, the number of Paneth cells is less than a preset threshold, neutrophilic granulocyte infiltration occurs, and the number of plasma cells remains unchanged, the to-be-detected person is determined to have autoimmune enteropathy; and when the number of plasma cells is less than a preset threshold, the to-be-detected person is determined to have common variant immunodeficiency. The application can effectively distinguish the types of rare intestinal diseases and has good clinical value.

This invention relates to anti-CD103 antibodies and their use in the diagnosis, prognosis, monitoring, and treatment of diseases. An imaging agent comprising the anti-CD103 antibody and a detectable label is also disclosed, wherein the antibody does not block CD103 binding to E-cadherin or at least partially blocks CD103 binding to E-cadherin. Treatment methods involve administering the anti-CD103 antibody, optionally conjugated to a cytotoxic agent. Diseases that need to be treated include, for example, hairy cell leukemia, HCLv, intestinal and extraintestinal lymphoma, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Cezari syndrome (SS), Alzheimer's disease, Parkinson's disease, or multiple sclerosis.

The present invention provides a method of treating a disease mediated by NLRP3 inflammasomes in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of compound 2′,4′-dihydroxychalcone. The compound 2′,4′-dihydroxychalcone inhibits the activation of NLRP3 inflammasomes and reduces the secretion level of pro-inflammatory factors by inhibiting the activation of Caspase-1 and the expression of NLRP3.

This invention discloses a magnetically guided probiotic-nanovesicle complex, its preparation method, and its applications, relating to the fields of biotechnology and medicine. The complex consists of turmeric-derived nanovesicles (Tur) and magnetically engineered probiotics (EcN@Fe3O4), which are directed to inflamed intestinal regions via an external magnetic field. This system exhibits significant anti-inflammatory and antioxidant effects, accelerates mucosal healing, restores intestinal microbiota balance, and possesses high biocompatibility and low toxicity. This invention provides a novel solution for the treatment of intestinal dysfunction and shows promising therapeutic effects on a range of inflammatory intestinal diseases.

This disclosure relates to genetically modified rodent animals and rodent models of human diseases. More specifically, this disclosure relates to genetically modified rodents whose genome comprises a humanized Il1rl2 gene (coding for the IL1rl2 subunit of the IL-36R protein) and human IL-36α, β and γ ligand genes. The genetically modified rodents disclosed herein display enhanced skin and intestinal inflammation as a preclinical model of psoriasis and IBD, respectively, and serve as a rodent model of human DITRA disease.